We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
HealthStream
HSTM
$814M
| $427K | 0.01% |
+15,785
| New | +$392K |
|
77
Bristol-Myers Squibb
BMY
$128B
| $424K | 0.01% |
+8,262
| New | +$434K |
|
78
Kimberly-Clark
KMB
$37B
| $423K | 0.01% |
+3,481
| New | +$421K |
|
79
Immersion
IMMR
$256M
| $417K | 0.01% |
+59,075
| New | +$393K |
|
80
Motorola Solutions
MSI
$70.3B
| $414K | 0.01% |
+1,323
| New | +$400K |
|
81
ITT
ITT
$17.7B
| $404K | 0.01% |
+3,383
| New | +$356K |
|
82
InterDigital
IDCC
$6.7B
| $403K | 0.01% |
+3,709
| New | +$343K |
|
83
TriSalus Life Sciences Warrant
TLSIW
$25.5M
| $397K | 0.01% |
333,333
| – | – |
|
84
Ralph Lauren
RL
$22.6B
| $392K | 0.01% |
+2,719
| New | +$337K |
|
85
Standard Motor Products
SMP
$867M
| $388K | 0.01% |
+9,754
| New | +$348K |
|
86
Euronet Worldwide
EEFT
$3.01B
| $387K | 0.01% |
+3,817
| New | +$326K |
|
87
Marcus Corp
MCS
$752M
| $387K | 0.01% |
+26,530
| New | +$398K |
|
88
Avery Dennison
AVY
$12.5B
| $365K | 0.01% |
+1,805
| New | +$337K |
|
89
Simply Good Foods
SMPL
$943M
| $364K | 0.01% |
+9,202
| New | +$344K |
|
90
Employers Holdings
EIG
$906M
| $359K | 0.01% |
+9,116
| New | +$355K |
|
91
Mativ Holdings
MATV
$455M
| $359K | 0.01% |
+23,447
| New | +$317K |
|
92
Amazon
AMZN
$2.49T
| $359K | 0.01% |
+2,361
| New | +$331K |
|
93
HCI Group
HCI
$2.25B
| $356K | 0.01% |
+4,070
| New | +$298K |
|
94
Ziff Davis
ZD
$1.93B
| $355K | 0.01% |
+5,288
| New | +$335K |
|
95
ANI Pharmaceuticals
ANIP
$1.78B
| $350K | 0.01% |
+6,347
| New | +$350K |
|
96
Supernus Pharmaceuticals
SUPN
$2.73B
| $347K | 0.01% |
+12,006
| New | +$318K |
|
97
FMC
FMC
$1.39B
| $347K | 0.01% |
+5,500
| New | +$319K |
|
98
MasterBrand
MBC
$1.12B
| $336K | 0.01% |
+22,602
| New | +$290K |
|
99
DaVita
DVA
$15.2B
| $335K | 0.01% |
+3,201
| New | +$296K |
|
100
Archrock
AROC
$6.26B
| $331K | 0.01% |
+21,524
| New | +$299K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.